Active acromegaly enhances spontaneous parathyroid hormone pulsatility

Metabolism: Clinical and Experimental

Volumn 55, Issue 6, 2006, Pages 736-740

  Mazziotti, Gherardo ^a   Cimino, Vincenzo ^b   De Menis, Ernesto ^c   Bonadonna, Stefania ^a   Bugari, Giovanna ^a   De Marinis, Laura ^b   Veldhuis, Johannes D ^d   Giustina, Andrea ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c Hospital of Treviso   (Italy)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

ACROMEGALY; ADULT; ARTICLE; BLOOD SAMPLING; BONE DEFECT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; ENTROPY; GONAD FUNCTION; GROWTH HORMONE BLOOD LEVEL; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; MALE; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PATIENT SELECTION; PRIORITY JOURNAL; PULSATILE HORMONE RELEASE; SAMPLE SIZE;

ACROMEGALY; ADULT; CASE-CONTROL STUDIES; ENTROPY; HUMANS; KINETICS; MALE; MIDDLE AGED; PARATHYROID HORMONE; PULSATILE FLOW;

EID: 33646527109     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.01.009     Document Type: Article

References (40)

1. Giustina A., and Veldhuis J.D. Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19 (1998) 717-797
2. Samuels M.H., Veldhuis J.D., Henry P., and Ridgway E.C. Pathophysiology of pulsatile and copulsatile release of thyroid-stimulating hormone, luteinizing hormone, follicle-stimulating hormone, and alpha-subunit. J Clin Endocrinol Metab 71 (1990) 425-432
3. Iranmanesh A., Lizzarralde G., Short D., and Veldhuis J.D. Intensive venous sampling paradigms disclose high frequency adrenocorticotropin release episodes in normal men. J Clin Endocrinol Metab 71 (1990) 1276-1283
4. Samuels M.H., Veldhuis J., Cawley C., Urban R.J., Luther M., Bauer R., et al. Pulsatile secretion of parathyroid hormone in normal young subjects: assessment by deconvolution analysis. J Clin Endocrinol Metab 76 (1993) 399-403
5. Harms H.M., Kaptaina U., Kulpmann W.R., Brabant G., and Hesch R.D. Pulse amplitude and frequency modulation of parathyroid hormone in plasma. J Clin Endocrinol Metab 69 (1989) 843-851
6. Kitamura N., Shigeno C., Shiomi K., et al. Episodic fluctuation in serum intact parathyroid hormone concentration in men. J Clin Endocrinol Metab 7 (1990) 252-263
7. Schmitt C.P., Schaefer F., Bruch A., et al. Control of pulsatile and tonic parathyroid hormone secretion by ionized calcium. J Clin Endocrinol Metab 81 (1996) 4236-4243
8. Bonadonna S., Burattin A., Nuzzo M., et al. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol 152 (2005) 199-205
9. Tam C.S., Heersche J.N.M., Murray T.M., and Parsons J.A. Parathyroid hormone stimulates apposition rate independently of its resorption action: differential effects of intermittent and continuous administration. Endocrinology 110 (1982) 506-512
10. Hock J.M., and Gera I. Effects of continuous and intermittent administration and inhibition of resorption on the anabolic response of bone to parathyroid hormone. J Bone Miner Res 7 (1992) 65-72
11. Hesch R.D., Busch U., Prokop M., Delling G., and Rittinghaus E.F. Increase of vertebral density by combination therapy with pulsatile l-38hPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 44 (1989) 176-180
12. Slovik D.M., Rosenthal D.I., Doppelt S.H., et al. Restoration of spinal bone in osteoporotic men by treatment by human parathyroid hormone (1-34) and 1,25 dihydroxy-vitamin D. J Bone Miner Res 1 (1986) 377-381
13. Samuels M.H., Veldhuis J.D., Kramer P., Urban R.J., Bauer R., and Mundy G. Episodic secretion of parathyroid hormone in post-menopausal women: assessment by deconvolution analysis and approximate entropy. J Bone Miner Res 12 (1993) 616-623
14. Ohlsson C., Bengtsson B.A., Isaksson O.G.P., Andreassen T.T., and Slootweg M.C. Growth hormone and bone. Endocr Rev 19 (1998) 55-79
15. Giustina A., Casanueva F.F., Cavagnini F., et al. Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26 (2003) 1242-1247
16. Colao A., Ferone D., Marzullo P., and Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25 (2004) 102-152
17. Aloja J.F., Roginsky M.S., Jowsey J., Dombrowski C.S., Shukla K.K., and Cohn S.H. Skeletal metabolism and body composition in acromegaly. J Clin Endocrinol Metab 35 (1972) 543-551
18. Halse J., Melsen F., and Mosekilde L. Iliac crest bone mass and remodelling in acromegaly. Acta Endocrinol 97 (1981) 18-22
19. Halse J., and Gordeladze J.O. Total and non-dialyzable urinary hydroxyproline in acromegalics and control subjects. Acta Endocrinol 96 (1981) 451-457
20. de la Piedra C., Larranaga J., Castro N., et al. Correlation among osteocalcin, growth hormone, and somatomedin C in acromegaly. Calcif Tissue Int 43 (1988) 44-45
21. Lowenthal M.N., Galinsky D., Fried V., Castel H., Shany S., and Gazit D. Acromegaly and proximal femoral fracture in an aged person: bone histomorphometry, vitamin D metabolites and parathormone. Isr J Med Sci 26 (1990) 280-283
22. Ezzat S., Melmed S., Endres D., Eyre D.R., and Singer F.R. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 76 (1993) 1452-1457
23. Legovini P., De Menis E., Breda F., et al. Long-term effects of octreotide on markers of bone metabolism in acromegaly: evidence of increased serum parathormone concentrations. J Endocrinol Invest 20 (1997) 434-438
24. Lesse G.P., Fraser W.D., Farquharson R., Hipkin L., and Vora J.P. Gonadal status in an important determinant of bone density in acromegaly. Clin Endocrinol 48 (1998) 59-65
25. Giustina A., Barkan A., Casanueva F.F., et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85 (2000) 526-529
26. Marcus R., Madvig P., and Young G. Age-related changes in PTH and PTH action in normal humans. J Clin Endocrinol Metab 58 (1984) 223-230
27. Hesch R.D., Braband G., Rittinghaus E.F., et al. Pulsatile secretion of parathyroid hormone and its action on type I and type II PTH receptor: a hypothesis for understanding osteoporosis. Calcif Tissue Int 42 (1988) 341-344
28. Biermasz N.R., Hamdy N.A., Pereira A.M., Romijn J.A., and Roelfsema F. Long-term skeleton effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin Endocrinol 60 (2004) 568-575
29. Giustina A., Bussi A.R., Jacobello C., and Wehrenberg W.B. Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 80 (1995) 122-129
30. Kasukawa Y., Miyakoshi N., and Mohan S. The anabolic effects of GH/IGF system on bone. Curr Pharm Des 10 (2004) 2577-2592
31. Kayath M.J., and Vieira J.G.H. Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int 7 (1997) 226-230
32. Scillitani A., Battista C., Chiodini I., et al. Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status. Clin Endocrinol 58 (2003) 725-731
33. Scillitani A., Chiodini I., Carnevale V., et al. Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res 12 (1997) 1729-1736
34. Bonadonna S., Mazziotti G., Nuzzo M., et al. Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20 (2005) 1837-1844
35. Ahmad A.M., Thomas J., Clewes A., et al. Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabolism. J Clin Endocrinol Metab 88 (2003) 2860-2868
36. Linkhart T.A., and Mohan S. Parathyroid hormone stimulates release of insulin-like growth factor-I (IGF-I) and IGF-II from neonatal mouse calvaria in organ culture. Endocrinology 125 (1989) 1484-1491
37. Johansson A.G., Baylink D.J., af Ekenstam E., Lindh E., Mohan S., and Ljunghall S. Circulating levels of insulin-like growth factor-I and -II, and IGF-binding protein-3 in inflammation and after parathyroid hormone infusion. Bone Miner 24 (1994) 25-31
38. Bikle D.D., Sakata T., Leary C., et al. Insulin-like growth factor I is required for the anabolic actions of parathyroid hormone on mouse bone. J Bone Miner Res 17 (2002) 1570-1578
39. Gasperi M., Cecconi E., Grasso L., et al. GH secretion is impaired in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 87 (2002) 1961-1964
40. Tanaka R., Tsushima T., Murakami H., Shizume K., and Obara T. Insulin-like growth factor I receptors and insulin-like growth factor-binding proteins in human parathyroid tumors. World J Surg 18 (1994) 635-641